Ozempic and other GLP-1s cut major cardiovascular events 13-26%, lower kidney disease risk, and reduce sleep apnea — but quitting for just 6 months erases most of the protection. A May 2026 meta-analysis of 90,000+ patients confirmed what cardiologists already suspected: the longer you stay on a GLP-1, the bigger the heart benefit. The catch: roughly 3 in 4 patients quit within a year, often because of cost — not because the drug stopped working.
Here's what the new data shows, why stopping is biologically more dangerous than most people realize, and the legitimate cheaper paths if money is the only reason you'd quit.
Is Ozempic actually safe long-term? The May 2026 evidence
Yes — and the long-term data now looks better than the short-term data. Two new analyses published in May 2026 stacked the case:
- Anglia Ruskin University meta-analysis (90,000+ participants): GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) by ~13% on average across all GLP-1 drugs combined.
- Pooled 60,000-patient meta-analysis: 14% MACE reduction, 12% reduction in all-cause mortality (death from any cause).
- Individual drug breakdown: Semaglutide (Ozempic/Wegovy) led with a 26% MACE reduction. Efpeglenatide followed at 27%. Dulaglutide and liraglutide cleared 10-15%.
- SELECT trial (Wegovy, 17,604 patients, 5 years): A statistically significant 20% lower risk of major cardiovascular events versus placebo in patients with established cardiovascular disease but no diabetes.
The pattern: the longer the trial, the bigger the benefit. Three-year continuous use produced an 18% cardiovascular risk reduction. That number is dose-independent — it's the time on therapy that matters most.
Why GLP-1s protect your heart (beyond weight loss)
The cardiovascular protection isn't just because you weigh less. GLP-1 receptors live in the heart, kidneys, blood vessels, and brain — not only in the gut. Long-term mechanism studies in 2024-2026 identified at least four protective effects independent of weight loss:
- Direct anti-inflammatory action on vascular endothelium (the lining of arteries). Less inflammation = slower atherosclerosis progression.
- Improved insulin sensitivity even in non-diabetics, which lowers downstream cardiovascular risk markers.
- Lower blood pressure — average drop of 4-6 mmHg systolic in trials, comparable to a low-dose blood pressure medication.
- Reduced visceral fat specifically (the dangerous fat around organs), which is more cardiovascular-toxic than subcutaneous fat.
This is why patients with normal BMI but established heart disease are increasingly being prescribed GLP-1s in 2026 — the heart benefit doesn't require obesity.
The kidney and sleep apnea bonus
The May 2026 European Congress on Obesity (ECO 2026) presented data from Optum Market Clarity covering ~280,000 GLP-1 patients. The headline: weight loss on GLP-1s tracks closely with reductions in obesity-related disease.
Compared to GLP-1 patients who lost less than 5% of their starting BMI, those who hit larger weight loss targets saw:
- Dramatically lower rates of obstructive sleep apnea — patients who lost 15%+ BMI cut OSA progression nearly in half.
- Lower chronic kidney disease incidence — particularly significant for patients with stage 1-2 CKD at baseline.
- Reduced osteoarthritis progression in weight-bearing joints (hip, knee).
- Lower rates of new heart failure diagnoses.
Kidney disease is where the financial math gets serious. The average annual cost of stage 4 CKD care in the US runs $30,000+. The average annual cost of dialysis exceeds $90,000. If a $99-$179/month GLP-1 program prevents progression from stage 2 to stage 4, that's an order-of-magnitude cost difference per year.
The reverse: what happens when you stop
This is the part patients aren't told often enough. The May 2026 weight-regain analysis found that patients who *gained* weight after starting a GLP-1 (typically because they discontinued the medication) had measurably higher disease rates compared to patients who lost less than 5% BMI:
- +10% risk of osteoarthritis
- +14% risk of chronic kidney disease
- +22% risk of obstructive sleep apnea
- +69% risk of heart failure
The 69% heart failure increase is the most striking finding. It suggests weight-cycling on/off GLP-1s may be worse for the heart than never starting at all — at least for patients with existing cardiometabolic risk.
A separate March 2026 CNBC-cited analysis found that stopping a GLP-1 for as little as 6 months raised cardiovascular risk by ~4% relative to continued use. The benefit is "leased," not owned — once the drug is gone, so is the protection.
How many patients actually stay on?
The discontinuation data is uncomfortable. Across major commercial claims databases, roughly 75% of GLP-1 starters quit within 12 months. The top three reasons (in order of frequency):
1. Cost (40-50% of discontinuations) — insurance dropped coverage, copay increased, or self-pay became unaffordable. 2. Side effects (20-25%) — usually GI symptoms during titration that often resolve but cause early exits. 3. Stopped losing weight / hit a plateau (15%) — typically a dose-titration problem, not a true plateau.
Only ~25% of these discontinuations are clinically appropriate (pregnancy, surgical complications, adverse events that don't resolve). The remaining 75% are cost or convenience exits — exactly the patients losing the cardiovascular and kidney protection without a good clinical reason.
If cost is the reason you'd quit, switch providers — don't stop the drug
For 24 million Americans who lost commercial GLP-1 coverage in 2025-2026, the right move isn't to abandon the medication. It's to find the cheapest legitimate path to the same active ingredient.
Compounded semaglutide and tirzepatide from US-licensed telehealth providers contain the same molecules as Ozempic, Wegovy, Mounjaro, and Zepbound. They're dispensed by 503A/503B pharmacies registered with the FDA. Pricing in May 2026:
- [Embody](/reviews/embody) — $99/month for compounded tirzepatide. Cheapest verified option, named-MD oversight, all 50 states.
- [SkinnyRx](/reviews/skinnyrx) — $129/month, multi-form GLP-1 (injectable, oral drops, lozenges, tablets), 150,000+ members, 10% weight-loss guarantee or refund.
- [Yucca Health](/reviews/yucca-health) — $146/month on a 6-month plan. LegitScript certified, 4.6/5 Trustpilot from 1,000+ patients, named physicians (Dr. Wasef MD, Dr. Sakla DO), Klarna and Affirm BNPL financing.
- [TrimRx](/reviews/trim-rx) — $179/month flat. Personalized doctor consultations, all-inclusive pricing with no hidden fees, unlimited check-ins, free shipping.
All four are tracked telehealth partners reviewed independently. For the full ranking with credentialing and clinical-oversight data, see our best GLP-1 programs comparison.
The "but is it actually the same molecule" question
Yes. Compounded semaglutide and compounded tirzepatide contain identical active pharmaceutical ingredients to their branded counterparts. The differences:
- Dose flexibility — compounded comes in dose-customizable vials rather than fixed-dose pens. Lets clinicians fine-tune titration.
- Excipients (inactive ingredients) may differ — the inactive carrier solution can vary by pharmacy.
- No FDA brand approval — the molecule has FDA approval (semaglutide/tirzepatide), but the specific compounded formulation does not.
- Pharmacy oversight — 503A pharmacies are state-board regulated; 503B outsourcing facilities are FDA-registered. Both are legal under the FDCA when actively prescribed.
The bigger risk is unverified compounders selling research-grade or imported APIs. Our FDA compounding crackdown coverage lists the providers flagged in 2026 enforcement waves — avoid those.
What this means if you're already on Ozempic, Wegovy, or Zepbound
Three practical takeaways from the May 2026 data:
1. Long-term use is protective, not risky. The fear that "Ozempic is too new for long-term safety" is now contradicted by 5-year SELECT data and 90,000-patient meta-analyses. The cardiovascular safety profile is favorable across the timeframes we have data for.
2. The benefit is leased. Quitting for 6+ months erases most of it. If you're considering stopping, talk to your prescriber about maintenance dosing (low-dose Wegovy maintenance is a viable path) before discontinuing entirely.
3. Cost is fixable; cardiovascular regression is harder to reverse. If your insurance dropped coverage or your copay is unaffordable, switch to a compounded path before you stop the drug. The math favors any-GLP-1 over no-GLP-1 by orders of magnitude when downstream cardiovascular and kidney costs are factored in.
Ozempic long-term safety FAQ
Is Ozempic safe to take for 5 years or longer?
The SELECT trial followed 17,604 patients on semaglutide for up to 5 years and found a 20% reduction in major cardiovascular events with a favorable safety profile. Real-world post-marketing surveillance through 2026 has not identified new long-term safety signals beyond known GI side effects, gallbladder events (rare), and the well-characterized hair-shedding effect tied to rapid weight loss. The longer-term data trends toward greater protection, not greater risk.
Does Ozempic reduce heart attack risk?
Yes. Semaglutide cut major adverse cardiovascular events — heart attack, stroke, cardiovascular death — by ~26% in pooled analyses and ~20% in the 5-year SELECT trial. The benefit appears whether or not the patient has type 2 diabetes.
Does Ozempic prevent kidney disease?
GLP-1s reduce the incidence and progression of chronic kidney disease in obese and diabetic patients, with the May 2026 ECO data showing the protective effect scales with weight loss magnitude. The FLOW trial (semaglutide in patients with diabetic kidney disease) showed a 24% reduction in kidney-related events and death.
What happens to my heart if I stop Ozempic?
A May 2026 meta-analysis showed that stopping a GLP-1 for as little as 6 months raised cardiovascular risk by 4% versus continued use. Patients who regained weight after stopping had a 69% higher risk of new heart failure compared to patients who maintained their loss.
Why do so many people stop Ozempic?
Cost is the largest driver — 40-50% of discontinuations are cost-related, not clinical. Side effects account for 20-25%, and perceived plateaus account for ~15%. Only about a quarter of stops have a clear medical justification.
Is compounded semaglutide as effective as Ozempic for heart protection?
The active ingredient is identical, so the pharmacology is the same. The cardiovascular outcome trials (SELECT, etc.) were run with branded semaglutide, so we don't have direct trial evidence for compounded versions specifically. The molecular mechanism — GLP-1 receptor agonism in cardiac and vascular tissue — is the same regardless of the dispensing pharmacy.
What's the cheapest legitimate GLP-1 program in 2026?
Embody at $99/month is the lowest verified price for compounded tirzepatide from a US-licensed telehealth provider with named-MD oversight. SkinnyRx at $129 and Yucca Health at $146 are the next-cheapest with stronger credentialing (LegitScript certification, BNPL financing). See our cheapest GLP-1 programs for the full ranking.
---
The bottom line: the May 2026 cardiovascular and kidney data makes long-term GLP-1 therapy harder to argue against on safety grounds, and harder to justify quitting purely for cost reasons. If you're on Ozempic, Wegovy, or Zepbound and considering stopping because of price — switch the provider, not the drug.
For the full provider ranking with credentialing, pricing, and clinical-oversight data, see our best GLP-1 programs comparison. For state-by-state insurance coverage, see our Medicare GLP-1 Bridge guide and insurance dropped GLP-1 coverage.